Deregulation of MYC expression occurs in many haematological malignancies. Previous studies modelling MYC-induced lymphomagenesis in the mouse used transgenic vectors that directed MYC overexpression in a lineage-specific manner. Here, we describe a transgenic mouse strain in which constitutive MYC expression is driven broadly in haemopoiesis by a vector containing regulatory elements of the Vav gene. Healthy young VavP-MYC17 mice had multiple haemopoietic abnormalities, most notably increased size and numbers of Blymphoid cells, monocytes and megakaryocytes. The mice rapidly developed tumours and, surprisingly, these were exclusively T-cell lymphomas, mostly of mature CD4 þ
Introduction
The transcription factor Myc plays a central role in controlling cell size, proliferation and differentiation (reviewed by Grandori et al., 2000; Boxer and Dang, 2001) . Expression of Myc is tightly cell-cycle regulated and, in response to cytokines or growth factors, Myc upregulation in G1 modulates the expression of an array of genes that promote cell growth and transition into S phase. Myc also sensitizes cells to diverse proapoptotic stimuli, a mechanism that is believed to limit the life of a cell with deregulated, potentially tumorigenic Myc expression (Evan and Littlewood, 1998) .
The involvement of MYC in human cancer was first established in Burkitt lymphoma where its constitutive expression in B cells results from a reciprocal chromosome translocation linking the MYC gene to an immunoglobulin locus (reviewed by Cory, 1986) . Subsequently, direct deregulation of MYC by translocation, mutation or amplification, or its overexpression as a result of mutations affecting upstream regulatory pathways, has been found in a variety of other malignancies. These include promyelocytic, B-cell acute lymphocytic, granulocytic, T-cell prolymphocytic and T-cell acute lymphoblastic leukaemias, plasma-cell neoplasms, large B-cell lymphoma (Marcu et al., 1992; Maljaie et al., 1995; Shou et al., 2000; Sanchez-Beato et al., 2003) , and other cancers, such as lung, breast and colon carcinoma (Grandori et al., 2000; Boxer and Dang, 2001) .
Transgenic tumour models have been used to investigate the mechanisms of tumorigenesis, to identify mutations that cooperate during tumour development and as tools to study responses to chemotherapy (Hann and Balmain, 2001 ). The Em-Myc transgenic mouse (Adams et al., 1985; Harris et al., 1988) , which models the Burkitt chromosome translocation by expressing Myc under the control of the Igh enhancer, has provided particular insight into Myc-induced tumorigenesis. In healthy young Em-Myc mice, the proliferative effects of Myc drive the polyclonal expansion pre-B-and Blymphocyte populations, but apoptosis restricts cell numbers as cytokine levels become limiting (Langdon et al., 1986; Adams et al., 1999) . Progression to full malignancy is dependent on disabling such apoptosis. Within a few weeks or months after birth, the mice develop clonal pre-B-cell or B-cell tumours as the Mycexpressing cells acquire somatic mutations, some of which negate the proapoptotic function of Myc by inactivating the p53-p19Arf-Mdm2 axis (Eischen et al., 1999) . Furthermore, lymphomagenesis in Em-Myc mice is markedly accelerated by overexpression of the antiapoptotic Bcl2 oncogene (Strasser et al., 1990) or by inactivation of proapoptotic genes such as those encoding the tumour suppressors p53, p19Arf or the Bcl2 antagonist Bim (Eischen et al., 1999; Schmitt et al., 1999; Egle et al., 2004) . Cooperating oncogenes have also been identified in retroviral insertional mutagenesis screens in Em-Myc mice, including the antiapoptotic Bmi1 gene that represses p19Arf and p16Ink4a expression (Mikkers and Berns, 2003) . Inactivation of the apoptotic programme controlled by p53 and p19Arf, or Bcl2 overexpression, compromises the response of Em-Myc tumours to chemotherapy (Schmitt et al., 1999 (Schmitt et al., , 2000 and analysis of Em-Myc tumours with defined antiapoptotic lesions is leading to an understanding of how tumour genotype can influence treatment outcome (Schmitt, 2003) .
The VavP transgenic vector incorporates regulatory elements of the Vav gene and drives stable expression in every nucleated haemopoietic cell type analysed, including both differentiated cells and progenitor cells (Adams et al., 1999; Ogilvy et al., 1999a, b) . Transgenic mice in which MYC expression is driven by the VavP vector will provide resources to compare MYC targets and susceptibility to malignant transformation in the various haemopoietic lineages, and will generate new, multilineage models of MYC-induced leukaemogenesis. Here the complex pretumour phenotype of a VavP-MYC transgenic mouse line is described, and the multilineage tumorigenic impact of the MYC transgene examined.
Results

Multilineage haemopoietic expression of transgenic MYC
Transgenic mice were generated by pronuclear microinjection of a human MYC cDNA into a Vav enhancer/ promoter vector ( Figure 1a ). Of the five primary transgenic mice (see Materials and methods), two succumbed to very early onset lymphoma, and sperm from one of them was used for in vitro fertilization to generate the line described here, designated VavP-MYC17. As anticipated, the VavP-MYC17 transgene was expressed in both lymphoid and myeloid cells. Western blot analysis revealed overexpressed MYC protein in thymocytes, splenocytes and bone marrow cells from healthy young mice and in sorted populations
, the expression being lower in myeloid than in lymphoid cells (Figure 1b) .
MYC expression can increase cell size, due to both intrinsic cell growth and entry into cycle (Iritani and 
, peripheral T cells, bone marrow pre-B cells, splenic B cells and blood monocytes (examples are shown in Figure 1c) , and megakaryocytes (Figure 1d ). The increased size of pre-B cells was not due to selective proliferation of the minor, CD43
þ fraction of normally large cells as this population was increased in number only slightly (1.7-fold). No consistent increase in the size of granulocytes (Figure 1c) Figure 2a , left panel; Table 1 ). By 4 weeks, however, the blood leucocyte count (and nucleated cell composition) had returned almost to normal ( Figure 2a , right panel). Perturbed homeostasis was also evident within the haemopoietic tissues of the 2-week-old transgenic mice ( Figure 2b ; Table 1 ). The spleen was three times larger than normal, due to substantial increases in both Blymphoid and erythroid cells. Strikingly, pre-B cells constituted approximately 40% of the splenic B-lineage cells. In the bone marrow, the most conspicuous change was the substantial increase in monocytes, apparently at the expense of erythropoiesis. The thymus appeared normal, both in cellularity and cell composition. Quantification of megakaryocytes in histological sections (20-35 high-power fields counted) from 2-week-old VavP-MYC17 mice and normal littermates revealed that these cells were much more abundant in transgenic spleen (7.170.6 per field vs 3.670.4, Po 0.001; overall increase was approximately sixfold due to the increased spleen size) and liver (1.070.2 per field vs 0.0270.02, Po0.001), but not bone marrow (3.670.3 per field vs 4.270.3, P ¼ 0.131).
VavP-MYC17 mice develop early onset T-cell lymphomas
All of the VavP-MYC17 mice monitored (23/23) succumbed to tumours between 7 and 10 weeks of age, and all of those analysed (22/22) were T-cell lymphomas: they expressed the T-lineage markers Thy1, TCRb and CD3, and lacked B-lymphoid (CD19), erythroid (Ter119) and myeloid (Mac1) markers (Figure 3a and c). The most frequently occurring lymphoma had the phenotype of a mature CD4 þ CD8 À T cell (12/22). Also seen were tumours of pre-T-cell (CD4 þ CD8 þ ) (4/22) and 'mixed T-cell' (3/22) origin; the latter contained both CD4 þ CD8 À and CD4 þ CD8 þ cells (Figure 3b and c). The variable latent period before tumour onset implied that each tumour had acquired somatic, cooperating, oncogenic mutations. The tumours of uniform phenotype presumably represented single transformed clones, whereas the 'mixed T-cell' tumours may have originated as separate clones, expected given the high rate of tumorigenesis in these mice. None of the tumours expressed the early activation markers CD25 or CD69, but all expressed the late Histological analysis indicated that the tumours had disseminated throughout the haemopoietic system, with frequent heavy invasion of the spleen (mean weight 1.070.1 vs 0.170.0 g in age-matched controls; n ¼ 28), thymus, bone marrow, lymph nodes and one or more Peyer's patches. Many sick mice also presented with leukaemia (mean leucocyte count 3776 Â 10 6 vs 971 Â 10 6 per ml in age-matched controls; n ¼ 32). The invaded bone marrow usually showed the 'starry sky' appearance (Morse et al., 2002) , thought to result from the engulfment of apoptotic tumour cells by macrophages. The liver, kidney and lungs commonly contained extensive tumour deposits, but the heart was only occasionally involved. Tumour cell morphology ranged, in a spectrum, from classic lymphoblastic (Morse et al., 2002) to immunoblastoid (Figure 3e and f), the latter with a large, vesicular nucleus containing a very large, strongly stained nucleolus, and moderately stained cytoplasm with readily visible cell borders. The frequency of mitotic figures (1271 mitoses per highpower field; X6 fields counted for tumours from 10 mice) was indicative of a high neoplastic grade. All eight tumours tested were readily transplantable.
Foetal liver reconstitution
In view of the multilineage abnormalities preceding tumorigenesis, it was surprising to find that the VavP-MYC17 mice developed only T-lineage lymphomas. Seeking to reveal a broader susceptibility to tumorigenesis, we undertook foetal liver reconstitution of lethally irradiated mice, during which myeloid precedes lymphoid regeneration. Liver cell suspensions from five E14 VavP-MYC17 foetuses were each injected into three lethally irradiated B6 mice. All 15 reconstituted mice rapidly developed tumours (median 14 weeks after transplantation) and, somewhat surprisingly, all 14 analysed were T-cell lymphomas (not shown). Two (derived from different foetal livers) were Thy1 þ TCRg/ d þ tumours, which may indicate that, during immune reconstitution, g/d T cells were a proportionally greater target for transformation. The other tumours were of the types seen in VavP-MYC17 mice (three CD4
, but differed by the predominance of pre-T lymphomas.
Rag1
À/À VavP-MYC17 mice develop a range of tumour types
As an alternative approach to determining whether other haemopoietic cell types in VavP-MYC17 mice were at risk of malignant transformation, we bred them with Rag1-deficient mice. The Rag1 recombinase gene is required for Tcr and Ig gene rearrangement and in its absence T-cell development is arrested at the pro-T3 stage (DN3 or pre-T1 in other nomenclatures) and Bcell development at the late pro-B stage (pre-B1 or Hardy fraction C) (Mombaerts et al., 1992b; Spanopoulou et al., 1994; Hardy and Hayakawa, 2001; Ceredig and Rolink, 2002; Marsden and Strasser, 2003) . While the Rag1 À/À VavP-MYC17 mice lived substantially longer than VavP-MYC17 mice, they all succumbed to tumours (median survival 13 weeks vs 8 weeks) (Figure 4 ). Cell surface analysis by flow cytometry identified four distinct tumour types in the 14 mice analysed: pro-B-cell, progenitor-cell, pre-T-cell and macrophage tumours.
Pro-B-cell tumours Six mice developed pro-B lymphomas, which bore the B-lineage markers B220 and CD19, and lacked T-lineage (Thy1, CD3), myeloid (Gr1, Mac1) and erythroid (Ter119) markers (Table 2 ). As they expressed HSA, BP-1, AA4.1, and CD43, but not CD25, they appear to have been derived from late pro-B cells. At autopsy, the mice had somewhat increased blood leucocyte counts (5.371.9 Â 10 6 per ml vs 1.470.1 Â 10 6 Tumours of multiple lineages in VavP-MYC17 mice DP Smith et al per ml in healthy young Rag1 À/À VavP-MYC17 mice) and typically had large tumour deposits in the thymus and lymph nodes, but with variable involvement of the spleen and bone marrow. Invasion of nonhaemopoietic tissues (including the liver, kidney, lung and heart) was generally limited. Histologically, the tumour cells were predominantly lymphoblastic (not shown).
Novel Thy1
þ B220 þ tumours Six mice developed unusual tumours that expressed high levels of both B220 and Thy1 and were also positive for the myeloid markers Gr1 and F4/80 (Table 2 ). This pattern of cell surface markers is suggestive of a multipotential progenitor. The presentation of these tumours was quite distinct from that of the pro-B lymphomas. The spleen was invariably greatly enlarged (mean weight 1.370.1 g), blood leucocyte counts were high (17.477.3 Â 10 6 per ml), very large tumour deposits were generally seen in the lymph nodes and bone marrow, and involvement of the thymus was variable. Tumour infiltration was common in the liver and lungs and, to a lesser extent, in the kidney and heart. The tumours had immunoblastoid morphology (not shown).
Pre-T-cell lymphomas Two Rag1
À/À VavP-MYC17 mice developed Thy1 þ T-lineage lymphomas. Surprisingly, both tumours had the phenotype of pre-T cells À/À VavP-MYC17 mice is delayed. VavP-MYC17 mice (n ¼ 23) were all sick within 10 weeks, with a median survival of 8 weeks, but Rag1 À/À VavP-MYC17 mice (n ¼ 18) showed a median survival of 13 weeks. Mice were monitored for tumours and killed when sick. The percentage of mice surviving at weekly intervals is shown Tumours of multiple lineages in VavP-MYC17 mice DP Smith et al (Figure 5a ; Table 2 ) rather than pro-T3 cells (Thy1
the earlier stage at which T-cell development is arrested in Rag1
À/À mice. The tumours also expressed CD44, a marker not normally present on pre-T cells, but expression of CD44 can reflect proliferation (Min et al., 2003) as well as developmental stage. They were confined to the thymus, with only minimal dissemination to the blood or tissues. Both were lymphoblastic in morphology (not shown).
The pre-T-cell phenotype of these tumours implied that they had by-passed the b-selection checkpoint that arrests Rag1 À/À thymocyte development at the pro-T3 stage. To investigate whether the differentiation block had been overcome prior to tumour onset, we analysed healthy 5-week-old mice (Figure 5b ). The thymus in Rag1 À/À VavP-MYC17 mice was as reduced in cell content as that of Rag1 À/À littermates, and the pro-T3 cell population was prominent, as expected. Significantly, there were no cells with the surface phenotype of pre-T cells. However, over 25% of cells in the Rag1
VavP-MYC17 thymus were a novel population not seen in the Rag1 À/À thymus. These cells expressed higher levels of Thy1 and CD4 than pre-T cells, and lower levels of CD25 than pro-T3 cells, and their surface phenotype (Thy1 hi CD4 hi CD8 À CD25 lo CD2 þ CD44 þ ) was distinct from any presently defined stage of T-cell development.
Cutaneous macrophage tumours The five longest surviving Rag1
À/À VavP-MYC17 mice developed cutaneous tumours that coexisted with progenitor cell tumours 
Flow cytometric signal intensity ranging from À to +++ is indicated. ND, not determined Tumours of multiple lineages in VavP-MYC17 mice DP Smith et al (three mice) and pre-T-cell lymphomas (two mice). The three tumours analysed expressed F4/80 and Mac1, but were negative for the granulocyte marker Gr1 (and other lineage markers including B220, CD19, Thy1, CD3 and Ter119) ( Figure 6a ; Table 2 ), implying that they were of monocyte/macrophage origin. Histologically, the tumours had the morphology of histiocytic sarcoma ( Figure 6b ) and each was confined to a single site except in one mouse where some lymph nodes were also involved. The tumours were locally invasive, investing the fat and muscle of the hypodermis and heavily populating the dermis. Of the four tumours tested, three were transplantable, spreading throughout the haemopoietic system and other organs such as the liver and kidney.
Discussion
In this study, we set out to explore the impact of deregulated MYC expression on different haemopoietic lineages. We have previously established that the VavP transgenic vector used here enforces expression in multiple haemopoietic cell types, including progenitor cells (Ogilvy et al., 1999a) and, as expected, exogenous MYC protein was detectable in T-and B-lymphoid cells, granulocytes and monocytes of VavP-MYC17 mice (Figure 1b) . Furthermore, cells of multiple haemopoietic lineages were larger than normal (Figure 1c, d) , consistent with MYC-promoted cell growth and/or increased cycling. Transplantation tests detected no tumour cells in 2-week-old VavP-MYC17 mice, but their haemopoietic system was markedly perturbed, most notably in the B-lymphoid, myeloid and megakaryocyte compartments (Figures 1d, 2a and b; Table 1 ). In the bone marrow, there was a marked increase in monocytes at the expense of erythroid cells. Indeed, erythropoiesis was largely displaced to the spleen, which also contained excessive numbers of B-lymphoid cells (both pre-B cells and mature B cells) and megakaryocytes. In addition, there was a 10-fold increase in blood leucocytes, primarily B-lymphoid cells and monocytes, although levels were almost normal by 4 weeks, perhaps reflective of more effective homeostatic control mechanisms by this age.
The VavP-MYC17 mice were highly prone to tumour development and succumbed before 10 weeks of age (Figure 4) . In view of the modest pretumour changes in the T-lymphoid compared to other lineages, we were surprised to find that all the tumours were T-cell lymphomas (Figure 3a and c) . Furthermore, in contrast to the CD4 þ CD8 þ pre-T-cell lymphomas typically seen in other Myc transgenic mice that develop T-lineage tumours, such as those expressing a CD2 promoterdriven (Stewart et al., 1993) or a tetracyclineinducible transgene (Felsher and Bishop, 1999) , most tumours in VavP-MYC17 mice were CD4 þ CD8 À T-cell lymphomas. The VavP-MYC17 T lymphomas expressed CD44 but were negative for other activation markers (CD25, CD69), and so the CD44 expression probably reflects multiple rounds of cell division (Min et al., 2003) . Intriguingly, the B-cell marker B220 was detected at low levels on a proportion of cells in some tumours (6/22) (Figure 3c and d) . Low B220 expression on T cells normally coincides with the approach of post-activation apoptosis (Renno et al., 1998) . This feature of VavP-MYC17 T-cell lymphomas may indicate, therefore, that acquisition of malignancy has involved the disabling of an apoptotic programme that normally eliminates T cells after multiple rounds of division.
Mouse models of mature CD4 þ CD8 À T-cell lymphoma are rare and the VavP-MYC17 mice may prove to be a useful tool. While their short lifespan presents breeding difficulties, these can be overcome by in vitro fertilization. Moreover, the tumours are readily transplantable and, like B-cell tumours transplanted from Em-Myc mice (Schmitt et al., 1999 (Schmitt et al., , 2000 , could be used to test for synergistic mutations and to study chemotherapy responses. In humans, T-cell chronic lymphocytic leukaemia and T-cell prolymphocytic leukaemia are largely diseases of CD4 þ CD8 À T cells (Harris et al., 1994) and share further surface character-
) with the VavP-MYC17 tumours (Figure 3c ). These leukaemias are associated with chromosomal rearrangements activating the expression of TCL1 and MTCP1 (Pekarsky et al., 2001) and, furthermore, trisomy 8q associated with increased MYC expression occurs frequently in Tcell prolymphocytic leukaemia (Maljaie et al., 1995) . Transgenic mice overexpressing TCL1 or MTCP1 in T cells usually developed late-onset CD4 À CD8 þ T-cell tumours, however, rather than the CD4 þ CD8 À neoplasms they aimed to model (Pekarsky et al., 2001) .
In the Rag1-deficient background, in which the T-cell populations most at risk of malignant transformation by the VavP-MYC17 transgene are absent, there was a dramatic shift to the development of multilineage tumours (Table 2) . Most were pro-B-cell lymphomas (43%) or unusual B220 þ Thy1 þ tumours (43%) rather than T-cell lymphomas (14%). In addition, many mice (36%) developed macrophage tumours along with the other tumour types. The latency of all these tumours was longer than that of the T-cell lymphomas in a Rag1-proficient background (Figure 4 ), indicating that, although multiple cell types are susceptible, T-cell lymphomas predominate overwhelmingly because they have the shortest latency. The differential transformation rate may reflect a combination of factors including the relative level of MYC overexpression in the various cell types, the size of the cell population at risk, the number of synergistic somatic mutations required for tumorigenesis and the ease with which they are acquired, and the proliferation rate of malignant clones.
The B220 þ Thy1 þ tumours in Rag1 À/À VavP-MYC17 mice (Table 2) are presumably derived from a rare progenitor cell although, to our knowledge, no normal counterpart of this cell type has yet been described and we have been unable to detect such a population in the spleen, thymus or bone marrow of healthy young VavP-MYC17 or Rag1 À/À VavP-MYC17 mice. While Em-BCL2-Myc bi-transgenic mice develop B220 þ Thy1 lo progenitor cell tumours (Strasser et al., 1996) , these differ from those described here in the expression of several surface markers. The histiocytic monocyte/macrophage tumours that developed in Rag1 À/À VavP-MYC17 mice (Figure 6a and b; Table 2 ) were cutaneous, with limited involvement of other tissues, suggesting that they arose by mutation of tissue-resident macrophages. However, on transplantation in syngeneic recipients, tumours spread throughout the haemopoietic system and other organs (including the liver and kidney) (not shown). Of note, the skin is a site for the rare human monocytic neoplasms -extramedullary myeloid cell tumour (monocytic subtype) and true histiocytic lymphoma (Elghetany, 1997) .
Two of the tumours that developed in Rag1 À/À VavP-MYC17 mice were pre-T-cell (CD4 þ CD8 þ ) lymphomas ( Figure 5a ; Table 2 ). This phenotype was unexpected because T-cell development in Rag1 À/À mice is blocked at the earlier pro-T3 stage by the b-selection checkpoint, which deletes cells lacking TCRb by apoptosis (Marsden and Strasser, 2003) . Certain genetic changes (both proliferative and anti-apoptotic) can force Rag1 À/À thymocytes through this checkpoint and partially restore thymus cellularity (Michie and Zuniga-Pflucker, 2002) . Since the thymus in healthy young Rag1 À/À VavP-MYC17 mice was as small as that in nontransgenic Rag1 À/À littermates and contained no pre-T cells (Figure 5b ), MYC overexpression per se does not overcome the b-selection block. Instead this checkpoint seems to have been by-passed during tumour development, perhaps by inactivation of the apoptotic machinery controlling this process.
Unexpectedly, in addition to pro-T3 cells, the premalignant thymus of 5-week-old Rag1 À/À VavP-MYC17 mice contained a significant number of cells having a surface phenotype (Thy1 hi CD4 hi CD8 À CD25 lo CD2 þ CD44 þ ) distinct from any previously described population of thymocytes (Figure 5b ). These cells may represent a MYC-driven expansion of an unrecognized intermediate stage in T-cell development. Cells of this type were not evident in the thymus of young VavP-MYC17 mice, but would only be expected to constitute at most 3% of the thymocytes. It is unclear whether the pre-T-cell tumours that arose in Rag1 À/À VavP-MYC17 mice derived from this unusual population of cells or from the pro-T3 population.
In summary, the VavP-MYC17 transgene perturbs the growth and proliferation of multiple lineages of haemopoietic cells. VavP-MYC17 mice should therefore be a useful resource for comparative studies of MYC targets in different haemopoietic cell types. In a wildtype background, the transgene promoted the rapid development of mature CD4 þ CD8 À T-cell lymphomas, which are rarely seen in other mouse models, and in the Rag1-deficient background macrophage, pro-B-cell and progenitor cell tumours developed. These mice therefore represent a new tool to study mechanisms of leukaemogenesis, synergism between genetic lesions, chemotherapeutic efficacy and chemoprevention in several haemopoietic tumour types. In the Rag1-deficient background, cell types that may be novel intermediates during haemopoietic development may also have been revealed. Crosses of VavP-MYC17 mice with other mutant strains (Mombaerts et al., 1992a; Nehls et al., 1994; von Freeden-Jeffry et al., 1995) deficient in T cells might yield further novel progenitor cell populations and tumour models.
Materials and methods
Transgene construction and generation of VavP-MYC mice
A human MYC cDNA, encompassing the coding region but lacking any 5 0 or 3 0 untranslated sequence (GenBank Accession number V00568; nucleotides 559 to 1878), was PCR amplified with primers that included SfiI (5 0 ) and NotI (3 0 ) linkers. The SfiI to NotI fragment was then cloned into the Vav enhancer/promoter vector (VavP) (Ogilvy et al., 1999a) ( Figure 1a ) and sequenced. The VavP-MYC construct was separated from the vector by HindIII digestion and injected into a pronucleus of C57BL/6J (B6) mouse zygotes, which were then transferred into pseudopregnant recipients. Transgenic offspring were identified by PCR of tail biopsy DNA using primers to the vector SV40 polyadenylation signal (gccgcagacatgataagatacatt and tcggctcgcgaggttttac). Five primary transgenic mice resulted. One died early of lymphoma without issue. Another also died early of lymphoma, but was used for in vitro fertilization to produce the VavP-MYC17 line described here, which expressed MYC at high levels. Two other primary mice produced descendant lines (to be described elsewhere) that expressed MYC at low levels and developed T lymphomas and/or macrophage tumours with longer latency. A fifth animal produced a line that expressed no detectable MYC.
Mice
All mice were of the B6 background and bred in the animal facilities of this institute. As female mice of the VavP-MYC17 transgenic line described here succumbed to lymphomas before completion of pregnancy or nursing, it was propagated by breeding transgenic males with normal B6 mice, either by natural mating or, when larger numbers were required, by in vitro fertilization (Bath, 2003) . Transgenic progeny was identified by PCR amplification of blood DNA and increased size of blood leucocyte nuclei.
Introduction of the VavP-MYC17 transgene into Rag1 À/À mice (Spanopoulou et al., 1994) was performed by in vitro fertilization; eggs from approximately 4-week-old VavP-MYC17 mice were fertilized with B6.Rag1 À/À sperm, and then eggs from approximately 4-week-old VavP-MYC17 Rag1 þ /À offspring were fertilized with Rag1 À/À sperm. The VavP-MYC17 transgene was detected by PCR, and Rag1 À/À mice were identified by their low blood leucocyte count.
To confirm the pretumour status of young transgenic mice, approximately 3 Â 10 6 viable cells dispersed from the thymus, spleen and bone marrow of 13-to 17-day-old mice were injected intraperitoneally into B6 mice (two mice per tissue) and the recipients monitored for tumour growth for at least 90 days.
Transplantation tests on tumours were performed by injecting approximately 2 Â 10 6 viable cells from dispersed tumour tissue both subcutaneously and intraperitoneally into B6 mice and monitoring recipients until they became sick or for at least 90 days.
For haemopoietic reconstitution experiments, cell suspensions were prepared from E14 foetal liver of VavP-MYC17 mice, and approximately 2 Â 10 6 viable cells were injected into the tail vein of lethally irradiated (2 Â 5.5 Gy spaced by 2 h) B6 mice.
For histological analysis, soft tissues were fixed in Bouin's, and bones in 10% buffered formalin. After standard processing, 2-mm tissue sections were stained with haematoxylin and eosin (H and E).
Nucleated cell counts and nuclear size distributions were determined with a Coulter Z2 particle count and size analyzer (Beckman Coulter).
